-+ 0.00%
-+ 0.00%
-+ 0.00%

GENENTECH’S FENEBRUTINIB IS THE FIRST BTK INHIBITOR TO RECEIVE U.S. FDA FILING ACCEPTANCE IN BOTH RELAPSING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS

Reuters·09/30/2026 05:02:05